This inventor holds 2 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents and 2 EPO patents. Top assignees: Merck Sharp & Dohme LLC, Merck Sharpe & Dohme Corp., Pfizer Corporation. Active years: 2020-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 70 
1 out of 36 
1 out of 4,488 
Years Active: 2020-2026
Title: Jean-Francois Andre Martini: Innovator in Cancer Treatment
Introduction
Jean-Francois Andre Martini is a notable inventor based in Carlsbad, CA (US). He has made significant contributions to the field of cancer treatment through his innovative research and development of combination therapies. His work focuses on enhancing the efficacy of cancer treatments by targeting specific receptors involved in tumor growth.
Latest Patents
Martini holds a patent for a groundbreaking invention titled "Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer." This patent describes combination therapies that include an antagonist of the Programmed Death 1 receptor (PD-1) and a VEGFR inhibitor. The therapies aim to treat cancers that express PD-L1, showcasing Martini's commitment to advancing cancer treatment options. He has 1 patent to his name.
Career Highlights
Throughout his career, Martini has worked with prominent pharmaceutical companies, including Pfizer Corporation and Merck Sharpe & Dohme Corp. His experience in these organizations has allowed him to collaborate with leading experts in the field and contribute to the development of innovative therapies.
Collaborations
Martini has collaborated with notable professionals such as Jamal Christo Tarazi and Rodolfo Fleury Perini. These partnerships have further enriched his research and development efforts in the realm of cancer treatment.
Conclusion
Jean-Francois Andre Martini is a distinguished inventor whose work in cancer treatment exemplifies innovation and dedication. His contributions through patented therapies are paving the way for more effective cancer treatments, ultimately benefiting patients worldwide.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile